Stablepoint Partners’s Novo Nordisk NVO Stock Holding History

Stablepoint Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Buy	25,914 +664	+3%	+$28.5K	0.17%	144
2026 Q1	$928K	Buy	25,250 +4,699	+23%	+$223K	0.14%	161
2025 Q4	$1.05M	Sell	20,551 -3,452	-14%	-$177K	0.16%	147
2025 Q3	$1.33M	Buy	24,003 +3,937	+20%	+$230K	0.21%	133
2025 Q2	$1.38M	Buy	20,066 +1,268	+7%	+$86.2K	0.24%	128
2025 Q1	$1.31M	Buy	18,798 +6,730	+56%	+$556K	0.24%	124
2024 Q4	$1.04M	Buy	12,068 +600	+5%	+$64.9K	0.19%	138
2024 Q3	$1.37M	Sell	11,468 -68	-0.6%	-$9.07K	0.25%	116
2024 Q2	$1.48M	Sell	11,536 -2,474	-18%	-$328K	0.29%	102
2024 Q1	$1.8M	Buy	14,010 +1,419	+11%	+$169K	0.36%	85
2023 Q4	$1.3M	Buy	+12,591	New	+$1.25M	0.33%	86

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Stablepoint Partners's NVO Position: Q2 2026 in Review

Stablepoint Partners increased its Novo Nordisk (NVO) stake by 2.6% in Q2 2026, buying an estimated $28.5K and bringing the position to 25,914 shares worth $1.24M. The position accounts for 0.17% of the portfolio, ranked #144.

Stablepoint Partners first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.8M in Q1 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Stablepoint Partners held 25,914 shares of Novo Nordisk worth $1.24M as of Q2 2026.
Stablepoint Partners bought 664 Novo Nordisk shares in Q2 2026, an estimated $28.5K.
Novo Nordisk made up 0.17% of Stablepoint Partners's portfolio in Q2 2026, its #144 holding.
Stablepoint Partners first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
Stablepoint Partners's Novo Nordisk position peaked at $1.8M in Q1 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Stablepoint Partners's 13F filing for Q2 2026, filed 9 Jul 2026.